Newsmaker – Bob Atwill

PERTH-BASED burns treatment-focused biomedical company Clinical Cell Culture Ltd has appointed Bob Atwill as chief executive. He replaces the company’s chief financial officer Andrew Cannon, who has been C3’s interim CEO, pending a permanent appointment. Mr Atwill and Mr Cannon will both take up positions on the company’s board. Mr Atwill, who will assume the position with immediate effect, will be based in Canberra and will split his time between C3’s operational headquarters in Cambridge, in the UK, and Australia. He is an experienced corporate executive with broad international experience in the pharmaceutical and medical services sectors, having worked in commercialising of medical devices in international markets. Mr Atwill was previously sales and marketing director of London Stock Exchange-listed Corin Group PLC, an orthopaedic products group, where he helped expand the business through organic growth, and strategic acquisitions. Mr Atwill has been in Australia since September 2005 and has consulted to biotech and biopharmaceutical companies on capital raisings and commercialisation strategies.